Day: June 22, 2026

Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3 

First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical...

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there...

error: Content is protected !!